Citations

Showing 10 of 108094 citations.

Wellness Coaching to Improve Lifestyle Behaviors Among Adults With Prediabetes: Patients’ Experience and Perceptions to Participation
DeJesus, Ramona S. , Clark, Matthew M. , Hathaway, Julie, Wilson, Patrick M. , Link, Sara, Hathaway, Julie C, Link, Sara M, Rutten, Lila J. Finney , Sauver, Jennifer L. St.

Mayo Clinic

Journal of Patient Experience | April 20, 2018 | Volume: 5 | Issue: 4 | Pages: 314-319

10.1177/2374373518769118 | PMID 30574554 Get It

Background: Health and Wellness Coaching has been shown to enhance treatment outcomes in the primary care setting. However, little is known about the experience and perceptions of patients who worked with a wellness coach as an integrated member of their primary health-care team. Objective: This project assessed patients’ experience and obtained their perceptions on barriers and facilitators to participation in a primary care–based wellness coaching program. Method: A survey was mailed to 99 primary care patients with prediabetes who participated in a 12-week wellness coaching program. Results: Sixty-two (63%) completed the survey; responders felt that participation in the wellness coaching program helped move them toward healthier lifestyle behavior and created a personal vision of wellness. Major themes associated with participation were supportive coaching relationship, increased self-accountability, increased goal-setting, and healthy behavior strategies. No significant barrier to participation was reported. Conclusion: Participants reported highly positive experience with the program; how to best integrate health and wellness coaching into the primary care setting needs to be explored.
Risks of restrictive red blood cell transfusion strategies in patients with cardiovascular disease (CVD): a meta‐analysis
Cortés‐Puch, Irene , Wiley, Brandon M. , Sun, Junfeng , Klein, Harvey G. , Welsh, Judith A., Danner, Robert L. , Eichacker, Peter Q. , Natanson, Charles , Natanson, C

Mayo Clinic

Transfusion Medicine | April 20, 2018 | Volume: 28 | Issue: 5 | Pages: 335-345

10.1111/tme.12535 | PMID 29675833 Get It

SUMMARY Aim To evaluate the risks of restrictive red blood cell transfusion strategies (haemoglobin 7–8 g dL −1 ) in patients with and without known cardiovascular disease (CVD). Background Recent guidelines recommend restrictive strategies for CVD patients hospitalised for non‐CVD indications, patients without known CVD and patients hospitalised for CVD corrective procedures. Methods/Materials Database searches were conducted through December 2017 for randomised clinical trials that enrolled patients with and without known CVD, hospitalised either for CVD‐corrective procedures or non‐cardiac indications, comparing effects of liberal with restrictive strategies on major adverse coronary events (MACE) and death. Results In CVD patients not undergoing cardiac interventions, a liberal strategy decreased ( P = 0·01) the relative risk (95% CI) (RR) of MACE [0·50 (0·29–0·86)] ( I 2 = 0%). Among patients without known CVD, the incidence of MACE was lower (1·7 vs 3·9%), and the effect of a liberal strategy on MACE [0·79, (0·39–1·58)] was smaller and non‐significant but not different from CVD patients ( P = 0·30). Combining all CVD and non‐CVD patients, a liberal strategy decreased MACE [0·59, (0·39–0·91); P = 0·02]. Conversely, among studies reporting mortality, a liberal strategy decreased mortality in CVD patients (11·7% vs·13·3%) but increased mortality (19·2% vs 18·0%) in patients without known CVD [interaction P = 0·05; ratio of RR 0·73, (0·53–1·00)]. A liberal strategy also did not benefit patients undergoing cardiac surgery; data were insufficient for percutaneous cardiac procedures. Conclusions In patients hospitalised for non‐cardiac indications, liberal transfusion strategies are associated with a decreased risk of MACE in both those with and without known CVD. However, this only provides a survival benefit to CVD patients not admitted for CVD‐corrective procedures.
Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)
Khoury, Paneez , Akuthota, Praveen , Ackerman, Steven J. , Arron, Joseph R. , Bochner, Bruce S. , Kahn, Jean‐Emmanuel , Fulkerson, Patricia C., Gleich, Gerald J. , Gopal-Srivastava, Rashmi, Jacobsen, Elizabeth A. , Leiferman, Kristen M, Francesca, Levi-Schaffer, Mathur, Sameer K. , Minnicozzi, Michael, Roufosse, Florence , Sable, Kathleen, Simon, Dagmar , Simon, Hans‐Uwe , Spencer, Lisa A. , Steinfeld, Jonathan , Wardlaw, Andrew J. , Weller, Peter F. , Bochner, Bruce S , Simon, Hans Uwe , Jacobsen, Elizabeth A , Collins, Margaret H. , Francesca, Levi-Schaffer, Prussin, Calman , Rothenberg, Marc E. , Wechsler, Michael E , Klion, Amy D.

Mayo Clinic

Journal of Leukocyte Biology | April 19, 2018 | Volume: 104 | Issue: 1 | Pages: 69-83

10.1002/jlb.5mr0118-028r | PMID 29672914 Get It

AbstractEosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.Review on eosinophil biology and eosinophil-related disorders (2012–2017) with a focus on continued unmet needs in eosinophil-associated diseases.
Patient-Rated Trust of Spine Surgeons: Influencing Factors
Haglin, Jack M. , Eltorai, Adam E. M. , Kalagara, Saisanjana , Kingrey, Brandon , Durand, Wessley M. , Aidlen, Jessica P., Daniels, Alan H.

Mayo Clinic

Global Spine Journal | April 19, 2018 | Volume: 8 | Issue: 7 | Pages: 728-732

10.1177/2192568218767385 | PMID 30443484 Get It

Study Design: Descriptive analysis using publicly available data. Objectives: The purpose of this study was 2-fold: to assess patient-rated trustworthiness of spine surgeons as a whole and to assess if academic proclivity, region of practice, or physician sex affects ratings of patient perceived trust. Methods: Orthopedic spine surgeons were randomly selected from the North American Spine Society directory. Surgeon profiles on 3 online physician rating websites, HealthGrades, Vitals, and RateMDs were analyzed for patient-reported trustworthiness. Whether or not the surgeon had published a PubMed-indexed paper in 2016 was assessed with regard to trustworthiness scores. Total number of publications was also assessed. Individuals with >300 publications were excluded due to the likelihood of repeat names. Results: Recent publication and total number of publications has no relationship with online patient ratings of trustworthiness across all surgeons in this study. Region of practice likewise has no influence on mean trust ratings, yet varied levels of correlation are observed. Furthermore, there was no difference in trust scores between male and female surgeons. Conclusion: Total academic proclivity via indexed publications does not correlate with patient perceived physician trustworthiness among spine surgeons as reported on physician review websites. Furthermore, region of practice within the United States does not have an influence on these trust scores. Likewise, there is no difference in trust score between female and male spine surgeons. This study also highlights an increasing utility for physician rating websites in spine surgery for evaluating and monitoring patient perception.
Cirrhotic Cardiomyopathy After Transplantation: Neither the Transient Nor Innocent Bystander
Izzy, Manhal , Oh, Jae K. , Watt, Kymberly D. , Oh, Jae

Mayo Clinic

Hepatology | April 19, 2018 | Volume: 68 | Issue: 5 | Pages: 2008-2015

10.1002/hep.30040 | PMID 29672903 Get It

Cirrhotic cardiomyopathy in end‐stage liver disease is currently characterized by blunted contractile systolic response to stress with or without diastolic dysfunction in the absence of known heart disease. Since the establishment of the diagnostic criteria of cirrhotic cardiomyopathy in 2005, there have been multiple studies regarding its pathophysiology and pretransplant clinical course. The data regarding the post‐transplant course of this entity are sparse. This review addresses the course and prognosis of the elements of cirrhotic cardiomyopathy after liver transplantation (LT). To this end, there is limited compelling evidence demonstrating the reversibility of this entity post‐LT. Cirrhotic cardiomyopathy may, in fact, increase the risk of post‐transplant complications. This review reveals a need to refine the diagnostic criteria of cirrhotic cardiomyopathy in view of the remarkable progress in the sphere of echocardiographic evaluation of systolic and diastolic dysfunction. The post‐transplant course and outcomes related to cirrhotic cardiomyopathy may be better evaluated in the setting of updated diagnostic criteria.
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
Maurer, Matthew J. , Ghesquières, Hervé , Link, Brian K. , Jais, Jean‐Philippe, Thompson, Carrie A. , Haïoun, Corinne , Allmer, Cristine, Johnston, Patrick B. , Delarue, Richard, Micallef, Ivana N. , Peyrade, Frédéric, Inwards, David J. , Ketterer, Nicolas , Farooq, Umar , Fitoussi, Olivier , Macon, William R. , Molina, Thierry Jo , Syrbu, Sergei , Weiner, George J. , Ansell, Stephen M. , Salles, Gilles , Tilly, Hervé , Nowakowski, Grzegorz S. , Molina, Thierry J, Salles, Gilles A, Maurer, Matthew , Link, Brian K , Farooq, Umar , Salles, Gilles A , Weiner, George , Jaïs, Jean‐Philippe , Habermann, Thomas M. , Feldman, Andrew L. , Slager, Susan L. , Cerhan, James R. , Witzig, Thomas E. , Syrbu, Sergei

Mayo Clinic

Journal of Clinical Oncology | April 19, 2018 | Volume: 36 | Issue: 16 | Pages: 1603-1610

10.1200/jco.2017.76.5198 | PMID 29672223 Get It

Purpose Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is concern that patients with clinically aggressive disease may not have enrolled in recent diffuse large B-cell lymphoma (DLBCL) trials due to the consent process and the inability to delay therapy for eligibility evaluation. We have examined the diagnosis-to-treatment interval (DTI) and its association with clinical factors and outcome in a clinic-based observational cohort of patients with DLBCL from the United States. Validation of results was performed in an independent, clinical trial-based cohort from Europe. Patients and Methods Patients were prospectively enrolled in the University of Iowa and Mayo Clinic Specialized Programs of Research Excellence Molecular Epidemiology Resource (MER; N = 986) or the Lymphoma Study Association (LYSA) LNH-2003 clinical trials program (N = 1,444). All patients received anthracycline-based immunochemotherapy at initial diagnosis. Associations of DTI with clinical factors and outcome were examined. Outcome was assessed using event-free survival at 24 months from diagnosis (EFS24). Results Median (range) DTI was 15 days (0 to 155 days in the MER and 23 days (0 to 215 days) in LYSA. Shorter DTI was strongly associated with adverse clinical factors, including elevated lactate dehydrogenase levels, poor performance status, B symptoms, and higher International Prognostic Index in both cohorts (all P < .001). Longer DTI was associated with improved EFS24 in both the MER (per-week odds ratio, 0.80; 95% CI, 0.74 to .0.87) and LYSA (per-week odds ratio, 0.90; 95% CI, 0.86 to 0.94); association with EFS24 remained significant after adjustment for International Prognostic Index. Conclusion DTI is strongly associated with prognostic clinical factors and outcome in newly diagnosed DLBCL. DTI should be reported in all clinical trials of newly diagnosed DLBCL and future trials should take steps to avoid selection bias due to treatment delay.
Resistive and elastic work of breathing in older and younger adults during exercise
Smith, Joshua R. , Cross, Troy J. , Iterson, Erik H. Van , Johnson, Bruce D. , Olson, Thomas P. , Van Iterson, Erik H , Smith, Joshua R , Cross, Troy James

Mayo Clinic

Journal of Applied Physiology | April 19, 2018 | Volume: 125 | Issue: 1 | Pages: 190-197

10.1152/japplphysiol.01105.2017 | PMID 29672228 Get It

It is unknown whether the greater total work of breathing (WOB) with aging is due to greater elastic and/or resistive WOB. We hypothesized that older compared with younger adults would exhibit a greater total WOB at matched ventilations (V̇e) during graded exercise, secondary to greater inspiratory resistive and elastic as well as expiratory resistive WOB. Older (OA: 60 ± 8 yr; n = 9) and younger (YA: 38 ± 7 yr; n = 9) adults performed an incremental cycling test to volitional fatigue. Esophageal pressure, inspiratory (IRV) and expiratory reserve volumes (ERV), expiratory flow limitation (EFL), and ventilatory variables were measured at matched V̇e (i.e., 25, 50, and 75 l/min) during exercise. The inspiratory resistive and elastic as well as expiratory resistive WOB were quantified using the Otis method. At V̇e of 75 l/min, older adults had greater %EFL and larger tidal volumes to inspiratory capacity but smaller relative IRV ( P ≤ 0.03) than younger adults. Older compared with younger adults had greater total WOB at V̇Eof 50 and 75 l/min (OA: 90 ± 43 vs. YA: 49 ± 21 J/min; P < 0.04 for both). At V̇e of 75 l/min, older adults had greater inspiratory elastic and resistive WOB (OA: 44 ± 27 vs. YA: 24 ± 22 and OA: 23 ± 15 vs. YA: 11 ± 3 J/min, respectively, P < 0.03 for both) and expiratory resistive WOB (OA: 23 ± 19 vs. YA: 14 ± 9 J/min, P = 0.02) than younger adults. These data demonstrate that aging-induced pulmonary alterations result in greater inspiratory elastic and resistive as well as expiratory resistive WOB, which may have implications for the integrated response during exercise.NEW & NOTEWORTHY Aging-induced changes to the pulmonary system result in increased work of breathing (WOB) during exercise. However, it is not known whether this higher WOB with aging is due to differences in elastic and/or resistive WOB. Herein, we demonstrate that older adults exhibited greater inspiratory elastic and resistive as well as expiratory resistive WOB during exercise.
Diaphragm plasticity in aging and disease: therapies for muscle weakness go from strength to strength
Greising, Sarah M. , Ottenheijm, Coen A. C. , O’Halloran, Ken D. , Barreiro, Esther

Mayo Clinic

Journal of Applied Physiology | April 19, 2018 | Volume: 125 | Issue: 2 | Pages: 243-253

10.1152/japplphysiol.01059.2017 | PMID 29672230 Get It

The diaphragm is the main inspiratory muscle and is required to be highly active throughout the life span. The diaphragm muscle must be able to produce and sustain various behaviors that range from ventilatory to nonventilatory such as those required for airway maintenance and clearance. Throughout the life span various circumstances and conditions may affect the ability of the diaphragm muscle to generate requisite forces, and in turn the diaphragm muscle may undergo significant weakness and dysfunction. For example, hypoxic stress, critical illness, cancer cachexia, chronic obstructive pulmonary disorder, and age-related sarcopenia all represent conditions in which significant diaphragm muscle dysfunction exits. This perspective review article presents several interesting topics involving diaphragm plasticity in aging and disease that were presented at the International Union of Physiological Sciences Conference in 2017. This review seeks to maximize the broad and collective research impact on diaphragm muscle dysfunction in the search for transformative treatment approaches to improve the diaphragm muscle health during aging and disease.
Misclassification of Upper Tract Urothelial Carcinoma in Patients With Lynch Syndrome—Reply
Samadder, N. Jewel , Wong, Jathine , Curtin, Karen

Mayo Clinic

JAMA Oncology | April 19, 2018 | Volume: 4 | Issue: 7 | Pages: 1010

10.1001/jamaoncol.2018.0545 | PMID 29710287 Get It

Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602)
Dockter, Travis , Lafky, Jacqueline M., Hurria, Arti , Muss, Hyman J., Cohen, Harvey Jay, Jatoi, Aminah , Kemeny, Margaret, Ruddy, Kathryn J. , Dockter, Travis J, Freedman, Rachel A.

Mayo Clinic

The Oncologist | April 19, 2018 | Volume: 23 | Issue: 9 | Pages: 1016-1023

10.1634/theoncologist.2018-0033 | PMID 29674441 Get It

Abstract Background There are multiple known individual- and practice-level barriers to enrollment of older patients with cancer to clinical trials, but little is known about how the clinical research workforce feels about potential higher-level strategy changes aimed to promote increased enrollment of older patients. Subjects, Materials, and Methods We invited all 11,351 Alliance for Clinical Trials in Oncology (“Alliance”) members to participate in an anonymous, web-based survey to examine awareness of current accrual patterns for older patients to clinical trials, to ascertain consensus on how to tackle enrollment challenges, and to provide the impetus for high-level changes to improve clinical trial accrual of older patients with cancer. Results During the period from February 28, 2017, to June 16, 2017, 1,146 Alliance members participated (response rate = 10%), including a national diverse sample of physicians, nurses, administrative/clinical research staff, and patient advocates with representation from community, academic, and rural sites. Overall, one third felt that &gt;50% of clinical trial enrollees should be age ≥65, and 64.9% felt the Alliance could improve upon enrollment of older patients. The four most commonly ranked strategies to improve enrollment of older patients were creating more dedicated trials for this population (36.3%), minimizing exclusion criteria focused on comorbidity (35.5%), developing independent strategies for those aged ≥65 and for those aged ≥70 (33.2%), and requiring that most/all Alliance trials have a specific expansion cohort of older patients (30.0%). Conclusion We anticipate that the recommendations from &gt;1,000 Alliance members will continue to propel important strategy changes aimed to improve accrual of older patients with cancer to clinical trials. Implications for Practice This survey of the Alliance for Clinical Trials membership sought opinions on potential, large-scale, national strategies to improve accrual of older adults with cancer. Consensus was found around multiple strategies, including creating more dedicated trials for older patients, developing less stringent eligibility criteria, and mandating expansion cohorts of older patients within broader Alliance trials. It is anticipated that the recommendations from &gt;1,000 Alliance members will continue to propel important strategy changes aimed to improve accrual of older patients with cancer to clinical trials.